<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39333882</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>High transmission of endemic human coronaviruses before and during the COVID-19 pandemic in adolescents in Cebu, Philippines.</ArticleTitle><Pagination><StartPage>1042</StartPage><MedlinePgn>1042</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1042</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-09672-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">SARS-CoV-2, the causative agent of COVID-19, is a betacoronavirus belonging to the same genus as endemic human coronaviruses (hCoVs) OC43 and HKU1 and is distinct from alpha hCoVs 229E and NL63. In a study of adolescents in the Philippines, we evaluated seroprevalence to the hCoVs, whether pre-pandemic hCoV immunity modulated subsequent risk of SARS-CoV-2 infection, and if SARS-CoV-2 infection affected the transmission of the hCoVs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From 499 individuals screened in 2021 for SARS-CoV-2 receptor binding domain (RBD) antibodies by enzyme-linked immunosorbent assay (ELISA), we randomly selected 59 SARS-CoV-2 negative and 61 positive individuals for further serological evaluation. We measured RBD and spike antibodies to the four hCoVs and SARS-CoV-2 by ELISA in samples from the same participants collected pre-pandemic (2018-2019) and mid-pandemic (2021), before COVID-19 vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed over 72% seropositivity to the four hCoVs pre-pandemic. Binding antibodies increased with age to 229E and OC43, suggesting endemic circulation, while antibody levels was flat across ages for HKU1 and NL63. During the COVID-19 pandemic, antibodies increased significantly to the RBDs of OC43, NL63, and 229E and spikes of all four hCoVs in both SARS-CoV-2 negative and positive adolescents. Those aged 12-15 years old in 2021 had higher antibodies to RBD and spike of OC43, NL63, and 229E than adolescents the same age in 2019, further demonstrating intense transmission of the hCoVs during the pandemic.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We observe a limited impact of the COVID-19 pandemic on endemic hCoV transmission. This study provides insight into co-circulation of hCoVs and SARS-CoV-2.</AbstractText><CopyrightInformation>© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Janet O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ylade</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines-Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daag</LastName><ForeName>Jedas Veronica</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines-Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aogo</LastName><ForeName>Rosemary</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crisostomo</LastName><ForeName>Maria Vinna</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines-Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mpingabo</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Premkumar</LastName><ForeName>Lakshmanane</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deen</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines-Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katzelnick</LastName><ForeName>Leah C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. leah.katzelnick@nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 CA260543</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>4U54CA260543</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Res Sq. 2023 Nov 16:rs.3.rs-3581033. doi: 10.21203/rs.3.rs-3581033/v1</RefSource><PMID Version="1">38014070</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010679" MajorTopicYN="N" Type="Geographic">Philippines</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">229E</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Endemic coronaviruses</Keyword><Keyword MajorTopicYN="N">HKU1</Keyword><Keyword MajorTopicYN="N">NL63</Keyword><Keyword MajorTopicYN="N">OC43</Keyword><Keyword MajorTopicYN="N">Philippines</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Seroprevalence</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>0</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39333882</ArticleId><ArticleId IdType="pmc">PMC11430261</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-09672-8</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-09672-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baloch S, Baloch MA, Zheng T, Pei X. The Coronavirus Disease 2019 (COVID-19) Pandemic. Tohoku J Exp Med. 2020;250:271–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32321874</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available at: https://data.who.int/dashboards/covid19/. Accessed 14 Aug 2024.</Citation></Reference><Reference><Citation>World Health Organization. Tracking SARS-CoV-2 variants. Available at: https://www.who.int/activities/tracking-SARS-CoV-2-variants. Accessed 14 Aug 2024.</Citation></Reference><Reference><Citation>Forni D, Cagliani R, Clerici M, Sironi M. Molecular Evolution of Human Coronavirus Genomes. Trends Microbiol. 2017;25:35–48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111218</ArticleId><ArticleId IdType="pubmed">27743750</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice BL, Douek DC, McDermott AB, Grenfell BT, Metcalf CJE. Why are there so few (or so many) circulating coronaviruses? Trends Immunol. 2021;42:751–63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8272969</ArticleId><ArticleId IdType="pubmed">34366247</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020;11:4704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499300</ArticleId><ArticleId IdType="pubmed">32943637</ArticleId></ArticleIdList></Reference><Reference><Citation>Edridge AWD, Kaczorowska J, Hoste ACR, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020;26:1691–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32929268</ArticleId></ArticleIdList></Reference><Reference><Citation>Galanti M, Shaman J. Direct Observation of Repeated Infections With Endemic Coronaviruses. J Infect Dis. 2021;223:409–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454749</ArticleId><ArticleId IdType="pubmed">32692346</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterlow NR, van Leeuwen E, Davies NG, Flasche S, Eggo RM, Group CC-W. How immunity from and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology. Proc Natl Acad Sci U S A. 2021;118(49):e2108395118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670441</ArticleId><ArticleId IdType="pubmed">34873059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoek LVD. Human Coronaviruses: What Do They Cause? Antiviral Ther. 2007;12(4 Pt B):651–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17944272</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockx B, Corti D, Donaldson E, et al. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol. 2008;82:3220–35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268459</ArticleId><ArticleId IdType="pubmed">18199635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Lusvarghi S, Subramanian R, et al. Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history. Cell Host Microbe. 2022;30(1745–58):e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9584854</ArticleId><ArticleId IdType="pubmed">36356586</ArticleId></ArticleIdList></Reference><Reference><Citation>Eguia RT, Crawford KHD, Stevens-Ayers T, et al. A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog. 2021;17:e1009453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8031418</ArticleId><ArticleId IdType="pubmed">33831132</ArticleId></ArticleIdList></Reference><Reference><Citation>Tso FY, Lidenge SJ, Pena PB, et al. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Int J Infect Dis. 2021;102:577–83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7648883</ArticleId><ArticleId IdType="pubmed">33176202</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamminen K, Salminen M, Blazevic V. Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults. Clin Immunol. 2021;229:108782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8188772</ArticleId><ArticleId IdType="pubmed">34118402</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray SM, Ansari AM, Frater J, et al. The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. Nat Rev Immunol. 2023;23:304–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9765363</ArticleId><ArticleId IdType="pubmed">36539527</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CJ, Chang SC. SARS-CoV-2 spike S2-specific neutralizing antibodies. Emerg Microbes Infect. 2023;12:2220582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10274517</ArticleId><ArticleId IdType="pubmed">37254830</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CY, Wolf J, Brice DC, et al. Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. Cell Host Microbe. 2022;30(83–96):e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648673</ArticleId><ArticleId IdType="pubmed">34965382</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat F, Clark J, Carreno JM, et al. Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination. J Virol. 2023;97:e0166422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10062180</ArticleId><ArticleId IdType="pubmed">36779758</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagar M, Reifler K, Rossi M, et al. Recent endemic coronavirus infection is associated with less-severe COVID-19. J Clin Invest. 2021;131(1):e143380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7773342</ArticleId><ArticleId IdType="pubmed">32997649</ArticleId></ArticleIdList></Reference><Reference><Citation>Aran D, Beachler DC, Lanes S, Overhage JM. Prior presumed coronavirus infection reduces COVID-19 risk: A cohort study. J Infect. 2020;81:923–30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7590640</ArticleId><ArticleId IdType="pubmed">33127456</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370:1339–43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857411</ArticleId><ArticleId IdType="pubmed">33159009</ArticleId></ArticleIdList></Reference><Reference><Citation>Galipeau Y, Siragam V, Laroche G, et al. Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2. EBioMedicine. 2021;74:103700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629681</ArticleId><ArticleId IdType="pubmed">34861490</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson EM, Goodwin EC, Verma A, et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell. 2021;184(1858–64):e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7871851</ArticleId><ArticleId IdType="pubmed">33631096</ArticleId></ArticleIdList></Reference><Reference><Citation>Selva KJ, van de Sandt CE, Lemke MM, et al. Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat Commun. 2021;12:2037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8016934</ArticleId><ArticleId IdType="pubmed">33795692</ArticleId></ArticleIdList></Reference><Reference><Citation>Saletti G, Gerlach T, Jansen JM, et al. Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. Sci Rep. 2020;10:21447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7722724</ArticleId><ArticleId IdType="pubmed">33293664</ArticleId></ArticleIdList></Reference><Reference><Citation>Antia R, Halloran ME. Transition to endemicity: Understanding COVID-19. Immunity. 2021;54:2172–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8461290</ArticleId><ArticleId IdType="pubmed">34626549</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21:162–77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh S, Govindarajulu M, Parise RS, et al. Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. Vaccines (Basel). 2021;9(10):1195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8537675</ArticleId><ArticleId IdType="pubmed">34696303</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamm P, Sagoschen I, Weise K, et al. Influenza and RSV incidence during COVID-19 pandemic-an observational study from in-hospital point-of-care testing. Med Microbiol Immunol. 2021;210:277–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8487758</ArticleId><ArticleId IdType="pubmed">34604931</ArticleId></ArticleIdList></Reference><Reference><Citation>Paget J, Caini S, Del Riccio M, van Waarden W, Meijer A. Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines? Euro Surveill. 2022;27(39):2200753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9524051</ArticleId><ArticleId IdType="pubmed">36177871</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos M, Wheatley AK, Laurie K, Kent SJ, Rockman S. Influenza lineage extinction during the COVID-19 pandemic? Nat Rev Microbiol. 2021;19:741–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8477979</ArticleId><ArticleId IdType="pubmed">34584246</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippine Department of Health COVID-19 Tracker. Available at: https://doh.gov.ph/diseases/covid-19/covid-19-case-tracker/. Accessed 22 Feb 2024.</Citation></Reference><Reference><Citation>Philippine Department of Health COVID-19 Vaccines. Available at: https://doh.gov.ph/diseases/covid-19/covid-19-vaccines/. Accessed 22 Feb 2024.</Citation></Reference><Reference><Citation>Sayama Y, Okamoto M, Saito M, et al. Seroprevalence of four endemic human coronaviruses and reactivity and neutralization capability against SARS-CoV-2 among children in the Philippines. Sci Rep. 2023;13:2310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9909632</ArticleId><ArticleId IdType="pubmed">36759702</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003;138:W1–12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12513067</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F, Srivastava K, Alshammary H, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021;384:1372–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008743</ArticleId><ArticleId IdType="pubmed">33691060</ArticleId></ArticleIdList></Reference><Reference><Citation>Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48):eabc8413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292505</ArticleId><ArticleId IdType="pubmed">32527802</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito D, Mehalko J, Drew M, et al. Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays. Protein Expr Purif. 2020;174:105686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271859</ArticleId><ArticleId IdType="pubmed">32504802</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Wang W, Wang H, Lu R, Tan W. First infection by all four non-severe acute respiratory syndrome human coronaviruses takes place during childhood. BMC Infect Dis. 2013;13:433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3848659</ArticleId><ArticleId IdType="pubmed">24040960</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt OW, Allan ID, Cooney MK, Foy HM, Fox JP. Rises in titers of antibody to human coronaviruses OC43 and 229E in Seattle families during 1975–1979. Am J Epidemiol. 1986;123:862–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110132</ArticleId><ArticleId IdType="pubmed">3008551</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgenlander WR, Henson SN, Monaco DR, et al. Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. J Clin Invest. 2021;131(7):e146927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8011893</ArticleId><ArticleId IdType="pubmed">33571169</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki A, Lupisan S, Furuse Y, et al. Respiratory viruses from hospitalized children with severe pneumonia in the Philippines. BMC Infect Dis. 2012;12:267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3519714</ArticleId><ArticleId IdType="pubmed">23092190</ArticleId></ArticleIdList></Reference><Reference><Citation>Dijkman R, Jebbink MF, Gaunt E, et al. The dominance of human coronavirus OC43 and NL63 infections in infants. J Clin Virol. 2012;53:135–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108278</ArticleId><ArticleId IdType="pubmed">22188723</ArticleId></ArticleIdList></Reference><Reference><Citation>Sechan F, Grobben M, Edridge AWD, et al. Atypical Antibody Dynamics During Human Coronavirus HKU1 Infections. Front Microbiol. 2022;13:853410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9093712</ArticleId><ArticleId IdType="pubmed">35572703</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Wang Y, Kang L, et al. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerg Microbes Infect. 2021;10:664–76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023607</ArticleId><ArticleId IdType="pubmed">33734013</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowley AR, Natarajan H, Hederman AP, et al. Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike. Elife. 2022;11:e75228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8923670</ArticleId><ArticleId IdType="pubmed">35289271</ArticleId></ArticleIdList></Reference><Reference><Citation>Narowski TM, Raphel K, Adams LE, et al. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. Cell Rep. 2022;38:110336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8769879</ArticleId><ArticleId IdType="pubmed">35090596</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>